Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.

By J. Nabholtz, A. Buzdar, Michael Pollak, W. Harwin, G. Burton, A. Mangalik, M. Steinberg, A. Webster, M. Voneuler. Journal of Clinical Oncology, 2000

1,012 citations recorded by the source corpus.

Subfields: Cancer Research, Endocrinology, Diabetes and Metabolism, Genetics

View Paper: https://www.semanticscholar.org/paper/c0111b5ea33e80f566e8094155a2828c62b528cf

Citations in the corpus

• ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) (2014, neutral): “500 mg, every 4 weeks) [77–88].”